RankAlpha logo
Back to Rankings

INCY

IncyteB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Underlying Q2 sales growth was positive: Jakafi rose 7% year over year and Opzelura, excluding the one-time CMS benefit, rose 24%. Constructive ESMO data and successful late-stage dermatology readouts could add pipeline value.
Posture
Constructive
Lead driver
Value
What changed
4 setup hits (3d) with net bullish as of 2026-10-27.
What can break
Atebrioz access or uptake may lag expectations, while Mirum—not Incyte—holds worldwide commercialization rights. [#PR-2026-09-25] Joint company release
Momentum
50
Value
67
Sentiment
56
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $115.00 · Bull $135.00 · Bear $90.00Analysis 2026-10-17; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-27

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $131.43
Why
Momentum50 · Δ7d +6.4
Value67 · Δ7d -0.2
Sentiment56 · Δ7d -1.7
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 4 setup hits (3d) with net bullish as of 2026-10-27.
  • • Next scheduled catalyst: earnings 2026-10-29 · BMO.
  • • Value remains the lead driver in the composite, 7D delta -0.2.

Contradictions & invalidation

  • • Atebrioz access or uptake may lag expectations, while Mirum—not Incyte—holds worldwide commercialization rights. [#PR-2026-09-25] Joint company release
  • • Early oncology data may be too immature or insufficiently differentiated to support the ongoing Phase 3 programs.
  • • The Q2 headline Opzelura figure overstates recurring growth because it includes a $246 million one-time benefit.

Catalyst clock

2026-10-29 · BMO

ESMO oncology data, October 23–26

Lead driver: Value · See fundamentals
Momentum
50
8% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
-19.2
Value
67
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.8
Sentiment
56
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
-17.4
Why this grade

Composite grade B. Momentum 50.2 / Value 67.1 / Sentiment 56.3

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method

B+
Bull case
25%
Probability
Target price
$135.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$90.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$23.63B
Beta
0.83
Shares Out
202.7M
P/E (TTM)
17.2
P/S (TTM)
4.15
P/FCF (TTM)
16.69
Rev YoY
+37.7%
EPS YoY
+38.0%
Gross Margin
+91.4%
Op Margin
+31.6%
Net Debt
-$3.53B
Current Ratio
4.59
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data